

Scott G Kitchen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/565996/publications.pdf>

Version: 2024-02-01

29
papers

1,795
citations

304602

22
h-index

434063

31
g-index

31
all docs

31
docs citations

31
times ranked

2926
citing authors

#	ARTICLE	IF	CITATIONS
1	Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. <i>Cell</i> , 2015, 163, 1716-1729.	13.5	322
2	Generation of HIV latency during thymopoiesis. <i>Nature Medicine</i> , 2001, 7, 459-464.	15.2	165
3	Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. <i>Journal of Clinical Investigation</i> , 2016, 127, 260-268.	3.9	153
4	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. <i>Molecular Therapy</i> , 2015, 23, 1358-1367.	3.7	111
5	Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. <i>PLoS Pathogens</i> , 2017, 13, e1006753.	2.1	91
6	CD4 on CD8+ T cells directly enhances effector function and is a target for HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8727-8732.	3.3	81
7	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2016, 90, 6999-7006.	1.5	80
8	In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells. <i>PLoS Pathogens</i> , 2012, 8, e1002649.	2.1	74
9	CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection. <i>Journal of Virology</i> , 2014, 88, 9934-9946.	1.5	63
10	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	7.3	60
11	Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. <i>Blood</i> , 2002, 99, 207-212.	0.6	56
12	Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice. <i>PLoS ONE</i> , 2009, 4, e8208.	1.1	51
13	Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e236.	2.3	51
14	Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. <i>PLoS Pathogens</i> , 2016, 12, e1005356.	2.1	49
15	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019, 25, 542-557.e9.	5.2	48
16	Stem cell-based anti-HIV gene therapy. <i>Virology</i> , 2011, 411, 260-272.	1.1	47
17	The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3794-3799.	3.3	44
18	Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. <i>Stem Cells and Development</i> , 2016, 25, 1863-1873.	1.1	37

#	ARTICLE	IF	CITATIONS
19	The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 746.	2.2	31
20	Engineering CAR T Cells to Target the HIV Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 410.	1.8	29
21	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 960-973.	3.7	24
22	Stem-Cell-Based Gene Therapy for HIV Infection. <i>Viruses</i> , 2014, 6, 1-12.	1.5	22
23	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. <i>PLoS Pathogens</i> , 2021, 17, e1009404.	2.1	19
24	Chimeric antigen receptor engineered stem cells: a novel HIV therapy. <i>Immunotherapy</i> , 2017, 9, 401-410.	1.0	17
25	Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. <i>AIDS Patient Care and STDs</i> , 2016, 30, 556-561.	1.1	14
26	New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. <i>Translational Research</i> , 2017, 187, 83-92.	2.2	13
27	Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	12
28	ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV. <i>PLoS Pathogens</i> , 2022, 18, e1010160.	2.1	10
29	Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV. <i>Aids</i> , 2021, 35, 543-553.	1.0	8